0	3	The	the	DT
4	16	Epstein-Barr	epstein-barr	JJ
17	22	virus	virus	NN
23	24	(	(	(
24	27	EBV	EBV	NNP
27	28	)	)	)
29	34	BMRF1	bmrf1	NN
35	43	promoter	promoter	NN
44	47	for	for	IN
48	53	early	early	JJ
54	61	antigen	antigen	NN
62	63	(	(	(
63	67	EA-D	EA-D	NNP
67	68	)	)	)
69	71	is	be	VBZ
72	81	regulated	regulate	VBN
82	84	by	by	IN
85	88	the	the	DT
89	92	EBV	EBV	NNP
93	108	transactivators	transactivator	NNS
108	109	,	,	,
110	115	BRLF1	BRLF1	NNP
116	119	and	and	CC
120	125	BZLF1	BZLF1	NNP
125	126	,	,	,
127	129	in	in	IN
130	131	a	a	DT
132	145	cell-specific	cell-specific	JJ
146	152	manner	manner	NN
152	153	.	.	.

155	158	The	the	DT
159	171	Epstein-Barr	epstein-barr	JJ
172	177	virus	virus	NN
178	183	early	early	JJ
184	191	antigen	antigen	NN
192	199	diffuse	diffuse	JJ
200	209	component	component	NN
210	211	(	(	(
211	215	EA-D	EA-D	NNP
215	216	)	)	)
217	219	is	be	VBZ
220	229	essential	essential	JJ
230	233	for	for	IN
234	246	Epstein-Barr	epstein-barr	JJ
247	252	virus	virus	NN
253	256	DNA	dna	NN
257	267	polymerase	polymerase	NN
268	276	activity	activity	NN
276	277	,	,	,
278	281	and	and	CC
282	285	its	its	PRP$
286	294	activity	activity	NN
295	297	is	be	VBZ
298	308	suppressed	suppress	VBN
309	315	during	during	IN
316	322	latent	latent	JJ
323	332	infection	infection	NN
332	333	.	.	.

334	336	We	we	PRP
337	349	investigated	investigate	VBD
350	353	the	the	DT
354	364	regulation	regulation	NN
365	367	of	of	IN
368	371	the	the	DT
372	380	promoter	promoter	NN
381	382	(	(	(
382	387	BMRF1	BMRF1	NNP
387	388	)	)	)
389	392	for	for	IN
393	397	this	this	DT
398	403	early	early	JJ
404	408	gene	gene	NN
409	411	by	by	IN
412	420	studying	study	VBG
421	424	its	its	PRP$
425	439	responsiveness	responsiveness	NN
440	442	in	in	FW
443	448	vitro	vitro	FW
449	451	to	to	TO
452	455	two	two	CD
456	471	immediate-early	immediate-early	JJ
472	477	viral	viral	JJ
478	493	transactivators	transactivator	NNS
493	494	,	,	,
495	500	BZLF1	BZLF1	NNP
501	502	(	(	(
502	503	Z	Z	NNP
503	504	)	)	)
505	508	and	and	CC
509	514	BRLF1	BRLF1	NNP
515	516	(	(	(
516	517	R	R	NNP
517	518	)	)	)
518	519	,	,	,
520	528	focusing	focus	VBG
529	531	on	on	IN
532	535	the	the	DT
536	547	differences	difference	NNS
548	550	in	in	IN
551	559	response	response	NN
560	562	in	in	IN
563	571	lymphoid	lymphoid	JJ
572	577	cells	cell	NNS
578	581	and	and	CC
582	592	epithelial	epithelial	JJ
593	598	cells	cell	NNS
598	599	.	.	.

600	602	In	in	IN
603	611	lymphoid	lymphoid	JJ
612	617	cells	cell	NNS
617	618	,	,	,
619	620	Z	Z	NNP
621	623	or	or	CC
624	625	R	R	NNP
626	631	alone	alone	RB
632	640	produced	produce	VBD
641	645	only	only	RB
646	651	small	small	JJ
652	661	increases	increase	NNS
662	664	in	in	IN
665	669	EA-D	EA-D	NNP
670	678	promoter	promoter	NN
679	687	activity	activity	NN
687	688	,	,	,
689	696	whereas	whereas	IN
697	701	both	both	DT
702	717	transactivators	transactivator	NNS
718	726	together	together	RB
727	735	produced	produce	VBD
736	737	a	a	DT
738	743	large	large	JJ
744	755	stimulatory	stimulatory	JJ
756	762	effect	effect	NN
762	763	.	.	.

764	766	In	in	IN
767	777	epithelial	epithelial	JJ
778	783	cells	cell	NNS
783	784	,	,	,
785	788	the	the	DT
789	790	Z	Z	NNP
791	805	transactivator	transactivator	NN
806	811	alone	alone	RB
812	820	produced	produce	VBD
821	828	maximal	maximal	JJ
829	840	stimulation	stimulation	NN
841	843	of	of	IN
844	847	the	the	DT
848	852	EA-D	EA-D	NNP
853	861	promoter	promoter	NN
861	862	;	;	:
863	866	the	the	DT
867	873	effect	effect	NN
874	876	of	of	IN
877	878	R	R	NNP
879	882	and	and	CC
883	884	Z	Z	NNP
885	893	together	together	RB
894	897	was	be	VBD
898	900	no	no	DT
901	908	greater	great	JJR
909	913	than	than	IN
914	918	that	that	DT
919	921	of	of	IN
922	923	Z	Z	NNP
924	929	alone	alone	RB
929	930	.	.	.

931	941	Deletional	deletional	JJ
942	950	analysis	analysis	NN
951	954	and	and	CC
955	968	site-directed	site-directed	JJ
969	980	mutagenesis	mutagenesis	NN
981	983	of	of	IN
984	987	the	the	DT
988	992	EA-D	EA-D	NNP
993	1001	promoter	promoter	NN
1002	1014	demonstrated	demonstrate	VBD
1015	1019	that	that	IN
1020	1022	in	in	IN
1023	1033	epithelial	epithelial	JJ
1034	1039	cells	cell	NNS
1040	1043	the	the	DT
1044	1053	potential	potential	JJ
1054	1058	AP-1	ap-1	NN
1059	1066	binding	binding	NN
1067	1071	site	site	NN
1072	1077	plays	play	VBZ
1078	1080	an	an	DT
1081	1090	essential	essential	JJ
1091	1095	role	role	NN
1096	1098	in	in	IN
1099	1100	Z	Z	NNP
1101	1115	responsiveness	responsiveness	NN
1115	1116	,	,	,
1117	1125	although	although	IN
1126	1135	sequences	sequence	NNS
1136	1143	further	further	RBR
1144	1152	upstream	upstream	RB
1153	1156	are	be	VBP
1157	1161	also	also	RB
1162	1171	important	important	JJ
1171	1172	.	.	.

1173	1175	In	in	IN
1176	1184	lymphoid	lymphoid	JJ
1185	1190	cells	cell	NNS
1190	1191	,	,	,
1192	1196	only	only	RB
1197	1200	the	the	DT
1201	1209	upstream	upstream	JJ
1210	1219	sequences	sequence	NNS
1220	1223	are	be	VBP
1224	1232	required	require	VBN
1233	1236	for	for	IN
1237	1252	transactivation	transactivation	NN
1253	1255	by	by	IN
1256	1259	the	the	DT
1260	1263	Z/R	Z/R	NNP
1264	1275	combination	combination	NN
1275	1276	,	,	,
1277	1280	and	and	CC
1281	1284	the	the	DT
1285	1289	AP-1	ap-1	NN
1290	1294	site	site	NN
1295	1297	is	be	VBZ
1298	1309	dispensable	dispensable	JJ
1309	1310	.	.	.

1311	1316	These	these	DT
1317	1321	data	datum	NNS
1322	1329	suggest	suggest	VBP
1330	1334	that	that	IN
1335	1339	EA-D	EA-D	NNP
1340	1341	(	(	(
1341	1346	BMRF1	BMRF1	NNP
1346	1347	)	)	)
1348	1356	promoter	promoter	NN
1357	1367	regulation	regulation	NN
1368	1370	by	by	IN
1371	1372	Z	Z	NNP
1373	1376	and	and	CC
1377	1378	R	R	NNP
1379	1381	is	be	VBZ
1382	1386	cell	cell	NN
1387	1391	type	type	NN
1392	1400	specific	specific	JJ
1401	1404	and	and	CC
1405	1412	appears	appear	VBZ
1413	1415	to	to	TO
1416	1423	involve	involve	VB
1424	1433	different	different	JJ
1434	1444	mechanisms	mechanism	NNS
1445	1447	in	in	IN
1448	1452	each	each	DT
1453	1457	cell	cell	NN
1458	1462	type	type	NN
1462	1463	.	.	.